High-Risk MIBC: Adjuvant Therapy Options After Radical Cystectomy

An expert discusses how adjuvant therapy options for high-risk muscle-invasive bladder cancer (MIBC); ypT2-ypT4a or N+) include cisplatin-based chemotherapy, which improves survival by targeting micrometastatic disease. Immune checkpoint inhibitors, such as atezolizumab and nivolumab, offer alternatives for cisplatin-ineligible patients.

EP: 1.MIUC: Risk of Recurrence After Radical Cystectomy

Now Viewing

EP: 2.High-Risk MIBC: Adjuvant Therapy Options After Radical Cystectomy

Video content above is prompted by the following:

• What are the adjuvant therapy options for patients with high-risk muscle invasive bladder cancer (ypT2-ypT4a or N+)?

Recent Videos